Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|SCUSF-0901||COG||SCUSF 0901 [ACCL0922] A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor||Pediatric CIRB||Available to Open|
|S9925||SWOG||Lung Cancer Specimen Repository Protocol Ancillary||Adult CIRB - Late Phase Emphasis||Completed|
|S9910||SWOG||Leukemia Centralized Reference Laboratories and Tissue Repositories Ancillary||Adult CIRB - Late Phase Emphasis||Completed|
|S2104||SWOG||Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|
|S2011||SWOG||Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|S2007||SWOG||A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases||Adult CIRB - Late Phase Emphasis||Available to Open|
|S2005||SWOG||A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoclax in Previously Untreated Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S2000||SWOG||A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1937||SWOG||A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1933||SWOG||A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status||Adult CIRB - Late Phase Emphasis||Available to Open|